Nalaganje...
Assessing Clinical Equivalence in Oncology Biosimilar Trials With Time-to-Event Outcomes
A typical biosimilar study in oncology uses the overall response evaluated at a specific time point as the primary endpoint, which is generally acceptable regulatorily, to assess clinical equivalence between a biosimilar and its reference product. The standard primary endpoint for evaluating an anti...
Shranjeno v:
| izdano v: | JNCI Cancer Spectr |
|---|---|
| Main Authors: | , , , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Oxford University Press
2019
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7050006/ https://ncbi.nlm.nih.gov/pubmed/32337484 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jncics/pkz058 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|